Literature DB >> 29129739

What Do "None," "Mild," "Moderate," "Severe," and "Very Severe" Mean to Patients With Cancer? Content Validity of PRO-CTCAE™ Response Scales.

Thomas M Atkinson1, Jennifer L Hay2, Amylou C Dueck3, Sandra A Mitchell4, Tito R Mendoza5, Lauren J Rogak2, Lori M Minasian4, Ethan Basch6.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 29129739      PMCID： PMC6317851          DOI： 10.1016/j.jpainsymman.2017.10.024

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN： 0885-3924            Impact factor:   3.612


× No keyword cloud information.
  8 in total

1.  Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding.

Authors:  Donald L Patrick; Laurie B Burke; Chad J Gwaltney; Nancy Kline Leidy; Mona L Martin; Elizabeth Molsen; Lena Ring
Journal:  Value Health       Date:  2011-10-10       Impact factor: 5.725

2.  Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument.

Authors:  Donald L Patrick; Laurie B Burke; Chad J Gwaltney; Nancy Kline Leidy; Mona L Martin; Elizabeth Molsen; Lena Ring
Journal:  Value Health       Date:  2011-10-13       Impact factor: 5.725

3.  Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch
Journal:  JAMA Oncol       Date:  2015-11       Impact factor: 31.777

4.  Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Authors:  Ethan Basch; Bryce B Reeve; Sandra A Mitchell; Steven B Clauser; Lori M Minasian; Amylou C Dueck; Tito R Mendoza; Jennifer Hay; Thomas M Atkinson; Amy P Abernethy; Deborah W Bruner; Charles S Cleeland; Jeff A Sloan; Ram Chilukuri; Paul Baumgartner; Andrea Denicoff; Diane St Germain; Ann M O'Mara; Alice Chen; Joseph Kelaghan; Antonia V Bennett; Laura Sit; Lauren Rogak; Allison Barz; Diane B Paul; Deborah Schrag
Journal:  J Natl Cancer Inst       Date:  2014-09-29       Impact factor: 13.506

Review 5.  Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Paul G Kluetz; Diana T Chingos; Ethan M Basch; Sandra A Mitchell
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

6.  Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Jennifer L Hay; Thomas M Atkinson; Bryce B Reeve; Sandra A Mitchell; Tito R Mendoza; Gordon Willis; Lori M Minasian; Steven B Clauser; Andrea Denicoff; Ann O'Mara; Alice Chen; Antonia V Bennett; Diane B Paul; Joshua Gagne; Lauren Rogak; Laura Sit; Vish Viswanath; Deborah Schrag; Ethan Basch
Journal:  Qual Life Res       Date:  2013-07-20       Impact factor: 4.147

7.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

8.  Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust.

Authors:  Johannes M Giesinger; Jacobien M Kieffer; Peter M Fayers; Mogens Groenvold; Morten Aa Petersen; Neil W Scott; Mirjam A G Sprangers; Galina Velikova; Neil K Aaronson
Journal:  J Clin Epidemiol       Date:  2015-09-28       Impact factor: 6.437
  8 in total
  9 in total

1.  Pilot randomized trial of an electronic symptom monitoring and reporting intervention for hospitalized adults undergoing hematopoietic stem cell transplantation.

Authors:  Ashley Leak Bryant; Erin Coffman; Brett Phillips; Xianming Tan; Elizabeth Bullard; Rachel Hirschey; Joshua Bradley; Antonia V Bennett; Angela M Stover; Lixin Song; Thomas C Shea; William A Wood
Journal:  Support Care Cancer       Date:  2019-06-20       Impact factor: 3.603

2.  Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer.

Authors:  Kirsten A Nyrop; Allison M Deal; Shlomit S Shachar; Ethan Basch; Bryce B Reeve; Seul Ki Choi; Jordan T Lee; William A Wood; Carey K Anders; Lisa A Carey; Elizabeth C Dees; Trevor A Jolly; Katherine E Reeder-Hayes; Gretchen G Kimmick; Meghan S Karuturi; Raquel E Reinbolt; JoEllen C Speca; Hyman B Muss
Journal:  Oncologist       Date:  2018-12-14

3.  Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer.

Authors:  Kirsten A Nyrop; Allison M Deal; Bryce B Reeve; Ethan Basch; Yi Tang Chen; Ji Hye Park; Shlomit S Shachar; Lisa A Carey; Katherine E Reeder-Hayes; Elizabeth C Dees; Trevor A Jolly; Gretchen G Kimmick; Meghan S Karuturi; Raquel E Reinbolt; JoEllen C Speca; Jordan T Lee; William A Wood; Hyman B Muss
Journal:  Cancer       Date:  2020-04-21       Impact factor: 6.860

4.  Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer.

Authors:  K A Nyrop; E M Damone; A M Deal; S B Wheeler; M Charlot; B B Reeve; E Basch; S S Shachar; L A Carey; K E Reeder-Hayes; E C Dees; T A Jolly; G G Kimmick; M S Karuturi; R E Reinbolt; J C Speca; W A Wood; H B Muss
Journal:  Breast Cancer Res Treat       Date:  2021-11-05       Impact factor: 4.872

5.  Application of a Bayesian graded response model to characterize areas of disagreement between clinician and patient grading of symptomatic adverse events.

Authors:  Thomas M Atkinson; Bryce B Reeve; Amylou C Dueck; Antonia V Bennett; Tito R Mendoza; Lauren J Rogak; Ethan Basch; Yuelin Li
Journal:  J Patient Rep Outcomes       Date:  2018-12-04

6.  OPEX: Development of a novel overall patient experience measure to facilitate interpretation of comparison effectiveness studies.

Authors:  Liana Fraenkel; Zhenglin Wei; Christine Ramsey; Carole Wiedmeyer; Kaleb Michaud; Tuhina Neogi; W Benjamin Nowell; Shilpa Venkatachalam; David A Broniatowski
Journal:  PLoS One       Date:  2021-01-29       Impact factor: 3.240

7.  Developing a Mobile Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events Administration System to Capture Postradiation Toxicity in Oncology: Usability and Feasibility Study.

Authors:  Jody Underwood; Ann Raldow; Amar Kishan; Chad Zalkin; Lisa Scott Holt; Andrew Webb; Kathleen A Lynch; Thomas M Atkinson; Susan McCloskey; Daniel Navarro
Journal:  JMIR Form Res       Date:  2022-04-12

8.  Ordinal labels in machine learning: a user-centered approach to improve data validity in medical settings.

Authors:  Andrea Seveso; Andrea Campagner; Davide Ciucci; Federico Cabitza
Journal:  BMC Med Inform Decis Mak       Date:  2020-08-20       Impact factor: 2.796

9.  Electronic Patient Symptom Management Program to Support Patients Receiving Cancer Treatment at Home During the COVID-19 Pandemic.

Authors:  Debra Wujcik; William N Dudley; Matthew Dudley; Vibha Gupta; Jeannine Brant
Journal:  Value Health       Date:  2022-03-23       Impact factor: 5.101
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.